Molecular Glues Market Size, Share & Industry Analysis, By Product (Thalidomide, Lenalidomide, Pomalidomide, and Others), By Application (Hematologic Malignancies, Solid Tumors, Autoimmune & Inflammatory Diseases, Neurological & Genetic Diseases, and Others) By Type (CRBN/Cereblon-based Molecular Glues, DCAF15-based Molecular Glues, Novel E3 Ligase-based Molecular Glues, and Others), By End User (Pharmaceutical & Biotechnology Companies, CROs/Drug Discovery Service Providers, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The molecular glues market size was valued at USD 6.68 billion in 2025. The market is projected to grow from USD 6.10 billion in 2026 to USD 10.56 billion by 2034, exhibiting a CAGR of 7.09% during the forecast period.

The market includes small-molecule treatments and discovery platforms that promote or stabilize protein or protein interactions to degrade or modify proteins that cause diseases. The market is growing in importance as pharmaceutical and biotechnology firms look for innovative methods to target proteins that were previously hard to drug in cancer, autoimmune, inflammatory, neurological, and genetic conditions. The existing market growth is primarily backed by CRBN/cereblon-based products, while anticipated growth is projected to stem from next-generation CELMoDs and innovative molecular glue degraders. Additionally, molecular glues are attracting interest as they are typically smaller and more similar to conventional drugs compared to bifunctional degraders such as PROTACs, facilitating oral administration and wider therapeutic advancements.

Key players operating in the market include Bristol-Myers Squibb Company, Monte Rosa Therapeutics, and C4 Therapeutics, Inc., and others. These companies are focusing on CRBN/CELMoD programs, DCAF15-based degraders, novel E3 ligase platforms, AI-enabled discovery engines, and strategic collaborations to expand molecular glue applications beyond hematologic malignancies into solid tumors and immune-mediated diseases.

MOLECULAR GLUES MARKET TRENDS

Expansion beyond Hematologic Malignancies is a Major Trend Observed in Market

The market is clearly expanding beyond hematologic malignancies as companies transition from established use cases in multiple myeloma, MDS, and lymphoma to wider disease areas including solid tumors, autoimmune disorders, inflammatory diseases, and genetic disorders. This change is significant as the initial commercial market heavily relied on CRBN/cereblon-related products such as lenalidomide and pomalidomide, whereas the upcoming growth stage needs broader target and indication expansion. Molecular glue degraders are drawing interest as they can eliminate disease-causing proteins that are challenging to target with traditional medications, thus creating possibilities in difficult-to-treat disease biology. The trend is aiding companies in decreasing reliance on traditional IMiD revenues that are experiencing generic erosion. With an increasing number of programs focusing on proteins such as VAV1, NEK7, GSPT1, ALK, and HuR, the market is anticipated to expand into areas involving immune-mediated diseases, inflammation, and solid tumors. This growth can broaden the patient base and enable high-value prospects for future molecular glue products. These factors are supporting the overall global molecular glues market growth.

• For instance, in October 2024, Novartis signed an exclusive development and commercialization agreement with Monte Rosa Therapeutics for MRT-6160, a VAV1-directed molecular glue degrader in Phase 1 development for immune-mediated diseases.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Need to Target Undruggable Disease Proteins to Boost Market Growth

The market is fueled by the increasing demand to tackle disease-related proteins that are hard to target with traditional small-molecule inhibitors or antibodies. Several proteins associated with cancer and immune regulation do not have distinct binding pockets or active sites for enzymes, which complicates direct inhibition. Molecular glues address this issue by positioning a disease protein near an E3 ligase, resulting in targeted protein degradation. This opens up broader possibilities for drug discovery, particularly in relapsed/refractory cancers and conditions with few treatment alternatives. Consequently, pharmaceutical and biotechnology firms are ramping up funding in CELMoDs and innovative molecular glue degraders to achieve objectives once deemed challenging or undruggable. This also promotes partnerships, platform advancement, and clinical pipeline growth in oncology and immune-mediated conditions.

• For instance, in May 2026, Bristol Myers Squibb reported positive Phase 3 results for mezigdomide, a CELMoD/molecular glue therapy in relapsed or refractory multiple myeloma. The company stated that mezigdomide works by binding cereblon and triggering degradation of cancer-driving proteins, and the trial showed a 52% reduction in the risk of disease progression or death when combined with carfilzomib and dexamethasone.

MARKET RESTRAINTS

Off-target Degradation and Safety Concerns to Limit Market Growth

Unintended degradation and safety concerns serve as a major limitation for the molecular glues market since these medications function by redirecting protein interactions instead of merely obstructing a single active site. If the molecular glue attracts undesired proteins to an E3 ligase, it may result in undesirable degradation and significant clinical toxicities. This risk is particularly significant for CRBN/cereblon-based medications, as hematologic toxicity, thromboembolism, embryo-fetal toxicity, neuropathy, hepatotoxicity, and immune-related effects may necessitate careful monitoring and dose adjustments. These safety issues can hinder physician acceptance, escalate regulatory demands, and boost the expenses and intricacies of clinical development. They also complicate the ability of next-generation molecular glues to progress into chronic inflammatory, autoimmune, neurological, or genetic diseases where expectations for long-term tolerability are greater than in late-line oncology. Consequently, businesses need to demonstrate not just significant target degradation but also a distinct safety margin, potentially hindering approvals and restricting wide market entry.

• For instance, in February 2025, the updated U.S. prescribing information for BMS’s Pomalyst/pomalidomide included a boxed warning for embryo-fetal toxicity and venous/arterial thromboembolism, stated that the product is available only through a restricted REMS program, and highlighted hematologic toxicity, with neutropenia reported as the most frequent Grade 3/4 adverse event.

MARKET OPPORTUNITIES

Growing Pipeline of Next-generation CELMoDs to Offer Lucrative Market Opportunities

The growing pipeline of next-generation CELMoDs is creating a strong market opportunity, as these products can help replace revenue lost from older IMiDs such as lenalidomide and pomalidomide after generic entry. These agents are designed to improve the depth, durability, and selectivity of protein degradation by modulating cereblon more effectively than earlier products. This is important as multiple myeloma and lymphoma still have high relapse rates, creating demand for oral therapies that can work after patients become resistant to existing treatments. A successful CELMoD pipeline can therefore extend the commercial life of CRBN-based molecular glues while opening new treatment lines and combination regimens. It also gives large pharma companies a way to defend their hematology franchise and build a next-generation product cycle. As these drugs move through late-stage trials and regulatory review, they are expected to support premium pricing and future market expansion. All these factors would drive the market growth in the coming years.

• For instance, in May 2026, Bristol Myers Squibb highlighted that iberdomide could become the first approved CELMoD by August 2026, while golcadomide was also being developed for lymphoma. This shows how BMS is building a next-generation CELMoD portfolio beyond Revlimid and Pomalyst to capture future growth in multiple myeloma and lymphoma.

MARKET CHALLENGES

Reimbursement and Pricing Pressure Pose a Prominent Challenge to Market Growth

Reimbursement and pricing pressure pose significant challenges for the market, as newer molecular glue degraders are anticipated to debut at high prices, while payers already offer less expensive generic IMiDs and various competing oncology alternatives. This results in a challenging access situation, particularly when new treatments need to demonstrate distinct clinical advantages over generic lenalidomide, pomalidomide, targeted antibodies, bispecifics, and cell therapies. In advanced markets, payers are expected to require robust evidence of progression-free survival, overall survival, quality of life, and safety prior to providing extensive reimbursement. In Europe and developing markets, HTA evaluations and budget limitations could further postpone the acceptance of next-generation molecular glues. The challenge holds particular significance for CRBN/CELMoD products since payers might directly compare them to older cereblon-based generics. As a result, companies may face slower uptake, lower net prices, and greater pressure to justify premium positioning. All the factors cumulatively affect the market growth.

• For instance, in November 2025, CMS announced negotiated Medicare prices for 15 high-cost drugs effective in 2027, including the molecular glue drug Pomalyst/pomalidomide. The reported negotiated price for Pomalyst was USD 8,650 for a 30-day supply, compared with a 2024 list price of USD 21,744, representing around a 60% reduction and showing direct pricing pressure on a key molecular glue product.

Segmentation Analysis

By Product

Lenalidomide Segment Dominated Due to Broad Hematologic Oncology Use and Established Commercial Base

In terms of product, the market is divided into pomalidomide, thalidomide, lenalidomide, and others.

The lenalidomide segment held the largest molecular glues market share in 2025. This is owing to its it wide use across key hematologic malignancies. Additionally, the segment leadership is supported by long-standing physician familiarity, oral administration, maintenance therapy uses in multiple myeloma, and broad regulatory approvals across major markets. Moreover, lenalidomide also benefited from its role as a backbone therapy in combination regimens, which helped sustain high patient volume even after generic entry.

• For instance, in February 2026, Bristol Myers Squibb stated that Revlimid/lenalidomide is approved for multiple hematologic malignancies including multiple myeloma, lymphoma, and MDS, and reported that generic lenalidomide products had entered the U.S., EU, and Japan markets, confirming the product’s broad commercial and treatment base despite ongoing generic erosion.

The pomalidomide segment is anticipated to rise with a CAGR of 5.48% over the forecast period.  

To know how our report can help streamline your business, Speak to Analyst

By Application

Hematologic Malignancies Segment Leads Due to Strong Use of Molecular Glues in Multiple Myeloma and Lymphoma

Based on application, the market is classified into hematologic malignancies, solid tumors, autoimmune & inflammatory diseases, neurological & genetic diseases, and others.

The hematologic malignancies segment accounted for the dominant market share in 2025. This can be attributed to the fact that approved molecular glue drugs such as lenalidomide, pomalidomide, and thalidomide have been primarily used in blood cancers, especially multiple myeloma, MDS, and lymphoma. The segment also benefits from strong physician familiarity, established treatment guidelines, and broad commercial availability of IMiD-based regimens. Moreover, hematologic malignancies have stronger clinical validation and a longer history of molecular glue use, which also aids in segment growth. Furthermore, the segment is set to hold 72.7% share in 2026.

• For instance, in May 2025, Bristol Myers Squibb highlighted clinical development of golcadomide, an investigational CELMoD agent for relapsed/refractory non-Hodgkin lymphoma, showing that molecular glue innovation remains strongly concentrated in hematologic malignancies beyond multiple myeloma.

The autoimmune & inflammatory diseases segment is anticipated to rise with a CAGR of 31.37% over the forecast period.  

By Type

Strong Clinical Validation and Commercial Use to Strengthen CRBN/Cereblon-based Molecular Glues Segment Dominance

On the basis of type, the market is divided into CRBN/cereblon-based molecular glues, DCAF15-based molecular glues, novel E3 ligase-based molecular glues, and others.

In 2025, the CRBN/cereblon-based molecular glues segment lead the market. This is owing to the fact that most of the currently approved products fall under this type. These products have established strong clinical use in hematologic malignancies, especially multiple myeloma, lymphoma, and MDS, which has made CRBN the most validated E3 ligase mechanism in the molecular glues field. The segment also benefits from next-generation CELMoDs, which continue to use cereblon biology while aiming to improve degradation activity and clinical outcomes. Furthermore, the segment is set to hold 78.4% share in 2026.

• For instance, in September 2025, Bristol Myers Squibb highlighted that its CELMoD agents act as molecular glues by altering the protein-binding properties of cereblon to promote interaction with and degradation of target proteins, and stated that it has built an industry-leading CELMoD library using computational and medicinal chemistry.

The DCAF15-based molecular glues segment is anticipated to rise with a CAGR of 27.74% over the forecast period.  

By End User

Pharmaceutical & Biotechnology Companies Segment Dominated Due to Strong Ownership of Commercial Products and Pipeline Programs

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, CROs/drug discovery service providers, academic & research institutes, and others.

The pharmaceutical & biotechnology companies segment dominated the market in 2025. These companies own most approved molecular glue products, late-stage CELMoD assets, and next-generation molecular glue degrader pipelines. Additionally, pharma and biotech companies capture a larger share of market value as they control product revenue, licensing rights, milestone payments, and commercialization opportunities. As the market expands beyond hematologic malignancies into oncology and immunology, pharma-biotech partnerships are expected to further strengthen this segment’s leadership. Furthermore, the segment is set to hold 68.3% share in 2026.

• For instance, in April 2026, Aurobindo Pharma’s subsidiary TheraNym Biologics announced an investment of around USD 150–175 billion to build a greenfield large-scale biologic drug substance manufacturing facility for MSD.

In addition, CROs/drug discovery service providers segment is projected to withness 11.28% growth rate during the forecast period.

Molecular Glues Market Regional Outlook

Based on region, the global market is divided into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market was vauled at USD 4.35 billion in 2024 and dominated the global market. In 2025, the region also maintained its leading position, with USD 3.09 billion revenue. The regional growth is driven by the strong uptake of premium hematology oncology therapies, high multiple myeloma treatment rates, and early adoption of next-generation CELMoDs and molecular glue degraders.

U.S. Molecular Glues Market

The U.S. market led the North American region and is projected to be approximately USD 2.56 billion in 2026, representing about 42.0% of the global market.

Europe

Europe market is expected to grow at a CAGR of 6.22% during the forecast period. Europe’s market growth is supported by established hematology treatment infrastructure, broad reimbursement coverage in major countries, and strong adoption of generic lenalidomide and pomalidomide across multiple myeloma and lymphoma indications.

U.K. Molecular Glues Market

The U.K. market in 2026 is estimated at around USD 0.31 billion, representing roughly 5.0% of global revenues.

Germany Molecular Glues Market

Germany market is projected to reach approximately USD 0.35 billion in 2026, equivalent to around 5.7% of global sales.

Asia Pacific

The Asia Pacific market is expected to reach a valuation of USD 1.25 billion by 2026. Asia Pacific is expected to show the fastest growth due to rising diagnosis of hematologic cancers, expanding oncology infrastructure, increasing access to generic IMiDs, and growing molecular glue innovation in China, Japan, South Korea, and India.   Additionally, the region also benefits from both volume-led growth through generics and innovation-led growth via novel molecular glue programs.

Japan Molecular Glues Market

The Japan market in 2026 is estimated at around USD 0.37 billion, accounting for roughly 6.1% of global revenues.

China Molecular Glues Market

China’s market is projected to reach revenues of around USD 0.42 billion in 2026, representing roughly 6.8% of global sales.

India Molecular Glues Market

The India market in 2026 is estimated at around USD 0.12 billion, accounting for roughly 1.9% of global revenues.

Latin America and Middle East & Africa

The growth in the Middle East & Africa and Latin America regions is anticipated to be moderate in the coming years. Key factors such as improving access to generic lenalidomide and pomalidomide, rising diagnosis of multiple myeloma and lymphoma, and gradual expansion of specialty oncology treatment centers are expected to boost the market growth in these regions. The Latin America market in 2026 is estimated at around USD 0.30 billion. In the Middle East Africa region, the GCC market is projected to reach approximately USD 0.10 billion by 2026, representing about 1.6% of worldwide revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Molecular Glue Pipelines and Discovery Platforms to Support Key Players’ Market Position

The molecular glues market reflects a concentrated but fast-evolving competitive landscape, consisting of major pharmaceutical companies and specialized biotechnology firms such as Bristol Myers Squibb Company, Monte Rosa Therapeutics, and C4 Therapeutics, Inc. The considerable market presence of these players is owing to their focus on CRBN/Cereblon-based CELMoDs, novel molecular glue degraders, DCAF15-based mechanisms, and AI/chemo proteomics-enabled discovery platforms. These companies are focusing on expanding molecular glue applications beyond hematologic malignancies into solid tumors, autoimmune diseases, inflammatory disorders, and immunology.

• For instance, in December 2025, Monte Rosa Therapeutics reported early clinical activity for MRT-2359, a GSPT1-directed molecular glue degrader, in combination with Pfizer’s Xtandi in castration-resistant prostate cancer, showing molecular glue expansion into solid tumors.

Other significant participants include Degron Therapeutics Co., Amphista Therapeutics, Neomorph, and Proxygen among others. These firms are also emphasizing strategic collaborations, next-generation CELMoD development, novel E3 ligase discovery, and outsourcing partnerships to improve target selection, accelerate clinical development, and expand molecular glue use across oncology and immune-mediated diseases.

LIST OF KEY MOLECULAR GLUES COMPANIES PROFILED

• Bristol-Myers Squibb Company (U.S.)
• Monte Rosa Therapeutics (U.S.)
• C4 Therapeutics, Inc. (U.S.)
• Degron Therapeutics Co. (China)
• TRIANA Biomedicines, Inc. (U.S.)
• Amphista Therapeutics (U.K.)
• GluBio Therapeutics Inc. (U.S.)
• Neomorph (U.S.)
• Proxygen (Autria)
• Captor Therapeutics (Poland)

KEY INDUSTRY DEVELOPMENTS

• December 2025: Degron Therapeutics started enrolling subjects in a first-in-human Phase 1 trial of DEG6498, a first-in-class HuR-targeting molecular glue degrader.
• November 2025: Evotec received a USD 5 million milestone payment from Bristol Myers Squibb after FDA acceptance of an IND under their strategic protein degradation partnership. The candidate is a CELMoD/molecular glue degrader, with Phase 1 expected to start in 2026.
• July 2025: Monte Rosa announced first subjects dosed in a Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases linked to NLRP3, IL-1β, and IL-6 dysregulation.
• May 2025: Genentech, a Roche subsidiary, entered into a partnership with Orionis Biosciences worth up to around USD 2.1 billion for development of a small-molecule protein degrader for cancer.
• January 2024: AION Labs unveiled TenAces Biosciences, a startup focused on molecular glue discovery using machine learning and data-driven approaches for targeted protein degradation.

REPORT COVERAGE

The global molecular glues market analysis includes a thorough evaluation of the market size and forecasts for every segment highlighted in the report. It offers insights into the market dynamics and trends expected to drive the market throughout the forecast period. The market report provides understanding of essential factors, including technological progress, product innovations, the regulatory environment, and the launch of new products. Additionally, it details partnerships, mergers & acquisitions, pipeline analysis, as well as key developments in the industry within the market. The market forecast report also provides an in-depth competitive landscape, including information on market share and profiles of key active players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation